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Abstract. Epithelial-to-mesenchymal transition (EMT) is 
a malignant cancer phenotype characterized by augmented 
invasion and metastasis, chemoresistance, and escape from 
host-immunity. This study sought to identify efficient 
methods for inducing EMT reversion, to evaluate altera-
tions in chemosensitivity and immune-protectiveness, and 
to elucidate the underlying mechanisms. In this study, the 
human lung adenocarcinoma cell lines PC-9 and HCC-827, 
harboring an EGFR mutation, were treated with TGF-β and 
FGF-2 to induce EMT. The phenotypic alterations were 
evaluated by RT-PCR, fluorescent immunohistochemistry, 
cell-mobility, and flow cytometry. Chemosensitivity to gefi-
tinib and cisplatin was evaluated using an MTT assay and 
apoptosis. Immune-protectiveness was evaluated by PD-L1 
expression. A combination of TGF-β and FGF-2 efficiently 
induced EMT in both cell lines: through Smad3 pathway 
in PC-9, and through Smad3, MEK/Erk, and mTOR path-
ways in HCC-827. The mTOR inhibitor PP242, metformin, 
and DMSO reverted EMT to different extent and through 
different pathways, depending on the cell lines. EMT induc-
tion reduced the sensitivity to gefitinib in both cell lines and 
to cisplatin in HCC-827, and it increased PD-L1 expression 
in both cell lines. EMT reversion using each of the 3 agents 
partly restored chemosensitivity and suppressed PD-L1 
expression. Thus, chemoresistance and increased PD-L1 
expression caused by EMT can be successfully reverted by 
EMT-reverting agents.
Introduction
The epithelial-to-mesenchymal transition (EMT) enables 
cancer to invade and metastasize (1,2). In addition, accumu-
lating evidence strongly suggests that the EMT induces cancer 
chemoresistance (3) and radioresistance (4,5) and has an 
immunoprotective effect (6). Therefore, the EMT constitutes 
a major malignant propensity to cancer development and is 
a major obstacle to curing cancer. TGF-β is a well-known 
driving factor of the EMT in many cancers (7). Activations 
of the Smad3, PI3K/Akt/mTOR, and MEK/Erk cascades 
are thought to be key mechanisms by which TGF-β induces 
EMT (8-11). FGF-2 also induces EMT through the activation 
of the MEK/Erk signaling pathway. Moreover, a combination 
of TGF-β and FGF-2 strongly induces EMT because TGF-β 
induces isoform switching of the FGF-receptor and increases 
cellular sensitivity to FGF-2 (12). All these signaling pathways 
ultimately upregulate the transcriptional factors slug, snail, 
and ZEB1, to induce EMT (13-15).
Recent advances in cancer biology have expanded thera-
peutic modalities to include cytotoxic chemotherapy, targeted 
therapy, and immune-checkpoint therapy. For example, the 
survival time of patients with advanced non-small cell lung 
cancer (NSCLC) harboring a mutation in either the epidermal 
growth factor receptor (EGFR) gene or the anaplastic 
lymphoma kinase (ALK) gene has been greatly prolonged using 
tyrosine kinase inhibitors (16) for the corresponding mutation. 
Nevertheless, cancer still recurs even after the drastic effects 
of targeted therapy. Although the mechanisms underlying drug 
resistance, either to cytotoxic or targeted agents, are not fully 
understood, they consist of mutational and non-mutational 
mechanisms. EMT is one of the non-mutational mechanisms 
of drug resistance (3). For example, EMT markers were report-
edly upregulated in patients with NSCLC showing resistance 
to cisplatin-based chemoradiotherapy (17). EMT is also report-
edly related to resistance to docetaxel in patients with prostate 
cancer (18). The results of several in vitro experiments have 
supported these clinical observations: EMT markers were 
upregulated in ovarian cancer cell lines resistant to paclitaxel 
(19), morphological changes suggesting EMT were observed 
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in colon cancer cells resistant to oxaliplatin (20), and the 
knockdown of snail increased the sensitivity of NSCLC cells 
to cisplatin (21). Therefore, the EMT appears to be closely 
related to resistance to cytotoxic agents. In addition, EMT is 
a candidate for the application of a non-mutational resistance 
mechanism to targeted therapy. The in vitro induction of EMT 
rendered human NSCLC cells harboring EGFR mutations less 
sensitive to EGFR-TKIs (22-24).
Therefore, EMT reversion to the original epithelial pheno-
type might be a new therapeutic strategy for overcoming 
resistance to chemotherapy and/or targeted therapy. Although 
some agents, including metformin and mTOR inhibitors, 
can reportedly revert the EMT phenotype, the relationship 
between this phenomenon and changes in drug sensitivity 
is not fully understood. This study examined the molecular 
mechanisms underlying EMT induction and reversion by 
investigating changes in drug sensitivity and immune-
protectiveness according to EMT induction and reversion in 
human lung adenocarcinoma cell lines harboring an EGFR 
mutation.
Materials and methods
Cells and reagents. Human lung adenocarcinoma cell lines, 
PC-9 and HCC-827, were used throughout the study. PC-9 was 
purchased from Riken Cell Bank (accession no. RCB4455; 
Tsukuba, Japan). HCC-827 was obtained from the American 
Type Culture Collection (accession no. CRL-2868; Manassas, 
vA, USA). The cell lines have an identical activating muta-
tion in EGFR: a deletion (del E746-A750) in exon 19. The 
cells were cultured as a monolayer in RPMI-1640 medium 
(cat. no. R8758; Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml 
penicillin and 100 mg/ml streptomycin (cat. no. 10378-016; 
Life Technologies, Carlsbad, CA, USA) in a 37˚C humidified 
atmosphere containing 5% CO2.
The EGFR-TKI gefitinib (cat. no. 3000; Tocris Bioscience, 
Ellisville, MO, USA) was dissolved in DMSO (cat. no. D2650; 
Sigma-Aldrich) and stored at -20˚C until use. Cisplatin at a 
concentration of 0.5 mg/ml (pH 2.5-5.5) was purchased from 
Nihon Kayaku (Tokyo, Japan) and stored at 4˚C. Metformin 
(1,1-dimethylbiguanide hydrochloride, cat. no. D150959-5G; 
Sigma-Aldrich) was dissolved in phosphate-buffered saline 
(PBS) at a concentration of 100 mM and stored at 4˚C. PP242 
(cat. no. 165-24441; wako, Osaka, Japan), a potent inhibitor of 
mTOR complex 1 and C2 (mTOR-C1 and -C2), was dissolved 
in DMSO at concentrations of 10 mM and stored in aliquots 
at -80˚C. Each agent was diluted in complete medium, and 
the final concentration of DMSO was <0.001%. Recombinant 
human TGF-β1 was purchased from PeproTech (cat. 
no. 100-21C; Rock Hill, NJ, USA), and recombinant human 
FGF-2 was purchased from Cell Signaling Technology (cat. 
no. 8910LC; Beverly, MA, USA).
Mouse monoclonal anti-β-actin (cat. no. A2228) and 
anti-fibronectin (cat. no. F3648) were purchased from Sigma-
Aldrich. Rabbit monoclonal anti-vimentin (cat. no. 5741P), 
anti-slug (cat. no. 9585S), anti-p70S6K (cat. no. 2708S), anti-
phospho-p70S6K (cat. no. 9205S), anti-Erk1/2 (cat. no. 9102S), 
anti-phospho-Erk1/2 (cat. no. 9101S), anti-Akt (cat. no. 9272S), 
anti-phospho-Akt on Ser473 (cat. no. 9271S), anti-Smad3 (cat. 
no. 9523S) and anti-phospho-Smad3 antibodies (cat. no. 9516S) 
were purchased from Cell Signaling Technology. The anti-E 
cadherin antibody was purchased from BD Transduction 
Laboratory (cat. no. 610181; Lexington, KY, USA). Anti-
PD-L1/CD274 monoclonal antibody was purchased from 
Spring Bioscience (cat. no. M4420; Pleasanton, CA, USA). 
Anti-rabbit IgG-horseradish peroxidase-linked antibody 
was purchased from Medical and Biological Laboratories 
(cat. no. 458; Nagoya, Japan). ECL™ horseradish peroxi-
dase linked anti-mouse antibody was purchased from GE 
Healthcare (cat. no. NA931; Uppsala, Sweden). Anti-mouse 
IgG Fab2 Alexa Fluor® 488 molecular probe (cat. no. 4408S) 
and anti-rabbit IgG Fab2 Alexa Fluor® 555 molecular 
probe (cat. no. 4413S) was purchased from Cell Signaling 
Technology.
In vitro induction and reversion of EMT. EMT was induced 
by treating cells with TGF-β and/or FGF-2. Based on a series 
of preliminary experiments, a combination of TGF-β at a 
concentration of 10 ng/ml and FGF-2 at a concentration of 
10 ng/ml was admixed into the complete medium for inducing 
EMT after 24 h of serum starvation. To evaluate the EMT 
phenotypes, cells harvested at 48 h after the admixture of the 
agents were used. For EMT reversion, PP242 at a concentra-
tion of 1.0, 10 or 100 nM, metformin at a concentration of 
0.1, 1.0 or 10 mM, or DMSO at a concentration of 0.1 or 1.0% 
(vol/vol) was added to cells in which the EMT had already 
been induced, with TGF-β/FGF-2 being supplemented contin-
uously. The phenotypes were evaluated after 72 h of culture 
with the reverting agent.
Evaluation of cell viability. Cell viability was determined 
using the MTT dye reduction method. A total of 500 cells/well 
were plated in 96-well culture plates. After 24 h of serum-free 
culture, the cells were treated to induce EMT and to revert 
EMT, as previously described. Then, the cells were treated 
with various concentrations of gefitinib or cisplatin for an 
additional 72 h of culture. To each well, 15 µl of dye solution 
(cat. no. G402A; Promega, Madison, wI, USA) was added for 
further incubation at 37˚C for 4 h, followed by the addition of 
100 µl of stop solution (cat. no. G4001; Promega) for a further 
1 h of incubation. The absorbance at 570 nm in the resulting 
solution was measured using Infinite® 200 PRO (FPRO-T; 
Tecan, Seestrasse, Switzerland). Cell viability was determined 
by dividing the absorbance value of the treated cells by that of 
the untreated cells.
Real-time PCR (RT-PCR). The expression of mRNA was 
semi-quantified using RT-PCR with the TaqMan® Gene 
Expression Assays, Step One Plus Real-Time PCR system, 
and Step One Software (Life Technologies). After culturing 
cells at 80% confluence in 6-well culture plates, the total 
RNA was extracted using the RNeasy® Mini kit (cat. 
no. 74104; Qiagen, venlo, Limburg, The Netherlands) and 
the cDNA was immediately synthesized using SuperScript® 
First-Strand Synthesis for RT-PCR (cat. no. 11904-018; Life 
Technologies) for RT-PCR according to the manufacturer's 
instructions. The gene expression data were calculated relative 
to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
level. TaqMan probes for GAPDH, E-cadherin, vimentin, 
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fibronectin, slug, and PD-L1 were obtained by ordering 
from Applied Biosystems through Life Technologies (assay 
identification numbers: Hs02758991_g1, Hs01023894_m1, 
Hs00185584_m1, Hs00365052_m1, Hs00950344_m1 and 
Hs01125301_m1).
Western blot analysis. Cells prepared in a manner similar to 
that used for the mRNA isolation studies mentioned above were 
lysed in RIPA buffer (cat. no. 89900; Thermo Fisher Scientific) 
with protease and phosphatase inhibitor (cat. no. 1861281; 
Thermo Fisher Scientific) on ice to extract the total protein. 
After measurement with a BCA assay (Pierce® BCA Protein 
assay kit, cat. no. 23225; Thermo Fisher Scientific, Rockford, 
IL, USA), 10 µg of protein in each lane in a 10% precast gel 
(Mini-PROTEAN® TGXTM, cat. no. 456-1025, Bio-Rad, 
Hercules, CA, USA) was electrophoresed using the Powger Pac 
Basic, Mini PROTEAN® Tetra System (Bio-Rad), followed 
by transfer to polyvinylidenedifluoride membranes (Trans-
Blot® TurboTM Transfer Pack 0.2 µm PvDF, cat. no. 170-4156; 
Bio-Rad) using the Trans-Blot Turbo™ Transfer System 
(Bio-Rad). The membranes were probed with antibodies using 
the iBind™ western Device, Cards and Solution kit (cat. 
no. SLF 1000, 1010 and 1020; Novex by Life Technologies), 
followed by visualization using an enhanced chemilumines-
cence substrate kit (Clarify™ western ECL Substrate, cat. 
no. 170-5060; Bio-Rad). The images were analyzed using 
Molecular imager® ChemiDOC™ XRS+ (Bio-Rad) and quan-
tified by Image Lab® Software (Bio-Rad). The expression of 
phosphorylated proteins was also determined as the relative 
ratio per total protein.
Fluorescent immunohistochemistry. For the fluorescent 
immunohistochemical evaluation of protein expression, cells 
were cultured up to 80% confluence in a 4-well chamber 
slide (cat. no. 177399; Thermo Fisher Scientific) and then 
washed with PBS and fixed with 4% paraformaldehyde at 
room temperature for 15 min, followed by incubation with 
the primary antibodies (diluted in PBS with 1% bovine serum 
albumin) at 4˚C overnight. Non-specific binding was blocked 
using 2% bovine serum albumin. Then, the cells were washed 
with PBS and incubated with secondary antibodies at room 
temperature for 30 min before being mounted in ProLong® 
Gold Antifade Reagent with 4', 6-diamidino-2-phenylindole 
(DAPI) (cat. no. 8961, Cell Signaling Technology) for observa-
tion with EvOS FL (AMF4300; Life Technologies).
Apoptosis assay. Apoptosis was examined using flow cyto-
metry with Annexin v-fluorescein isothiocyanate (FITC) 
and propidium iodide (PI) (cat. no. 556547; BD Biosciences, 
San Jose, CA, USA). Briefly, cells were treated with various 
concentrations of gefitinib or cisplatin for 24 h, trypsinized, 
washed with cold PBS, and suspended in binding buffer 
(BD Biosciences) at a concentration of 1x107 cells/ml. 
Thereafter, they were stained with 5 µl of Annexin v-FITC 
and 5 µl of PI in 100 µl of cell suspension and incubated for 15 
min at room temperature in the dark for processing using flow 
cytometry. All the early apoptotic cells (Annexin v-positive, 
PI-negative), necrotic/late apoptotic cells (double posi-
tive), and living cells (double negative) were counted using 
FACSCanto IITM (BD Biosciences).
Cell cycle. The cell cycle distributions were determined using 
a PI single-color flow cytometry (FACSCanto II), according to 
the manufacturer's instructions. Briefly, cells were trypsinized 
and washed twice with cold PBS, then fixed with 70% ethanol. 
Before analysis, the cell suspensions were washed with PBS, 
suspended in 100 µl of binding buffer containing 5 µl of PI at 
a concentration of 1x107 cells/ml, followed by incubation for 
15 min at room temperature in the dark.
Wound healing assay. The cell migration ability was evalu-
ated using a wound healing assay. Cells were cultured until 
they became confluent in 6-well plates, at which time the 
surfaces of the plates were scratched with micropipette tips 
(cat. no. 2069-05; Thermo Fisher Scientific) and the culture 
medium was immediately exchanged, followed by culture for 
a further 9 h. The scratched wounds were viewed using an 
inverted microscope (x10 objective) (ECLIPSE TS100; Nikon, 
Tokyo, Japan). The scratched areas were quantified using 
Image J (from National Institutes of Health), and the wound 
closure rates were determined as a percentage of the total 
repaired area per hour and were normalized to the control.
Statistical analyses and ethical considerations. Data are 
presented as the means ± standard errors, and differences 
between groups were evaluated using the Student's t-test. A 
P-value of <0.05 (2-tailed) was considered statistically signifi-
cant. All the experiments were conducted in close adherence 
to the institutional regulations.
Results
In vitro induction of EMT. The EMT phenotype was confirmed 
by a decreased expression of E-cadherin (an epithelial 
marker) and an increased expression of vimentin, fibronectin 
(mesenchymal markers), and slug. RT-PCR for the HCC-827 
cells revealed that TGF-β upregulated vimentin, fibronectin, 
and slug without downregulating E-cadherin; that FGF-2 
downregulated E-cadherin without upregulating vimentin, 
fibronectin, and slug; and that the combination of TGF-β and 
FGF-2 downregulated E-cadherin and upregulated vimentin, 
fibronectin, and slug, resulting in a perfect EMT phenotype. 
In the PC-9 cells, in contrast, the combination of TGF-β and 
FGF-2 upregulated vimentin, fibronectin, and slug without 
downregulating E-cadherin (Fig. 1A). The altered expressions 
of E-cadherin at the cell junctions and of fibronectin in the 
cytoplasm were further confirmed using fluorescent immuno-
histochemistry, except that the PC-9 cells failed to show any 
change in E-cadherin expression (Fig. 1B). The morphological 
changes in the cells were concordant with these observations: 
that is, the HCC-827 cells became elongated in morphology 
and less adhesive when they exhibited the EMT phenotype, 
whereas the PC-9 cells were unaltered in morphology, since 
the original cells were already ostensibly elongated and less 
adhesive (Fig. 2A). A wound healing assay disclosed increased 
cell-mobility for the EMT phenotype in both cell lines (Fig. 2B). 
The accumulation of G0/G1 cells in the EMT phenotype was 
observed in a cell cycle analysis (Fig. 2C). These findings 
clearly indicate the successful induction of EMT in both cell 
lines. Based on this fact, the combination of TGF-β and FGF-2 
was used to induce EMT in the remainder of this study.
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Figure 1. Evidence of EMT induction and reversion as assessed by changes in the expressions of E-cadherin, vimentin, fibronectin, and slug in the human 
adenocarcinoma lung cancer cell lines, HCC827 and PC9. (A) The relative ratio of mRNA normalized to that in the control was evaluated using RT-PCR for 
cells treated with/without TGF-β (10 ng/ml) and/or FGF-2 (10 ng/ml). The treatment duration was 48 h after a 24-h serum starvation period. TGF-β alone and 
the combination of TGF-β/FGF-2 showed comparable effects on increasing the expression of the mesenchymal markers and slug in both cell lines, whereas 
the combination, but not TGF-β alone, was effective in decreasing E-cadherin expression in HCC827. The combination was thereafter used to induce EMT 
throughout the study. In addition, PP242 (1.0, 10 or 100 nM), metformin (0.1, 1.0 or 10 mM), and DMSO (0.1 or 1.0%) reverted the altered expression of these 
markers. Of note, treatment with these 3 drugs was started in cells that were already exhibiting EMT induction. The columns and bars represent the means and 
SEs (n=6, in triplicate) of the relative ratios compared with the controls, respectively. Statistically significant differences (P<0.05) compared with the control 
(no TGF-β/FGF-2) and TGF-β/FGF-2-treated cells are indicated by * and ¶, respectively. (B) The changes in E-cadherin expression on the cell surface and the 
changes in fibronectin expression in the cytoplasm were confirmed using fluorescent immunohistochemical staining. The doses for PP242, metformin, and 
DMSO were 100 nM, 1.0 mM, and 1.0%, respectively. Cells were counterstained with DAPI. The bars represent 50 µm.
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Figure 2. Phenotypic alterations according to EMT induction and reversion. (A) The combination of TGF-β/FGF-2 (10 ng/ml, each) induced clear morpho-
logical changes in HCC-827, resulting in an elongated and less-adhesive appearance; in contrast, the morphology of the PC-9 cells was unaltered, since the 
original cells already exhibited an elongated and less-adhesive appearance. The bars represent 50 µm. (B) A wound healing assay disclosed enhanced cell 
motility after treatment with TGF-β/FGF-2 in both cell lines, whereas PP242, metformin, and DMSO at the same doses as those used in Fig. 1B suppressed 
the phenomenon, as shown by the representative phase contrast images on the left. For quantification, the distance of cell migration was measured after 9 h 
in 3 fields (n=9, in triplicate) for each group; the results are presented on the right. Statistically significant differences (P<0.05) compared with the control 
(no TGF-β/FGF-2) and TGF-β/FGF-2-treated cells are indicated by * and ¶, respectively. (C) FACS analyses demonstrated a significant accumulation at the 
G0/G1 phases together with a significant decrease in the S and G2/M phases in TGF-β/FGF-2-treated cells in both cell lines. PP242, metformin, and DMSO at 
the same doses as those used in Fig. 1B reverted these alterations. Statistically significant differences (P<0.05) compared with the control (no TGF-β/FGF-2) 
and TGF-β/FGF-2-treated cells are indicated by * and ¶, respectively. (D) MTT assays for PP242, metformin, and DMSO revealed dose-dependent growth 
inhibition of the cells. Based on the results, the dose ranges for these 3 agents were determined so that growth inhibition was not so significant within these 
dose ranges. The dots and bars represent the means and SEs (n=3, in triplicate), respectively.
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Reversion of EMT induction. For the EMT reversion that was 
induced as described above, PP242, metformin, and DMSO 
were used. Because these agents are known to be cytotoxic, 
the cell survival curves resulting from the use of these agents 
Figure 3. Phosphorylation of EMT-related pathway molecules in EMT induction and reversion. (A) Immunoblotting for phosphorylated Smad3, Erk1/2, 
p70S6K, and Akt (Ser473) and a β-actin control revealed the pathway-specific activation of these molecules. (B) Relative quantification of the blots shown 
in (A). As stated in detail in the text, EMT induction and reversion occurred via different pathways, depending on the cell lines and reverting agents. The 
columns and bars represent the means and SEs (n=3, in triplicate), respectively. Statistically significant differences (P<0.05) compared with the control (no 
TGF-β/FGF-2) and TGF-β/FGF-2-treated cells are indicated by * and ¶, respectively.
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were determined using an MTT assay (Fig. 2D). Based on the 
resulting data, doses of 1.0, 10, or 100 nM for PP242; 0.1, 1.0, 
or 10 mM for metformin; and 0.1 or 1.0% (vol/vol) for DMSO 
were chosen because their cytotoxicity was considered not 
to be very high at these doses. Although none of the agents 
significantly increased the expression of E-cadherin through 
EMT reversion in the PC-9 cells, PP242 and metformin 
administered at the lowest concentrations tended to increase 
E-cadherin expression in the HCC-827 cells. The three 
agents significantly decreased the expressions of vimentin, 
fibronectin, and slug in both cell lines (Fig. 1A). Fluorescent 
immunohistochemistry studies also supported the findings in 
HCC-827 cells: treatment with PP242, metformin, or DMSO 
suppressed the expression of fibronectin in the cytoplasm, 
with E-cadherin expression on the surface being unaltered 
(Fig. 1B). A wound healing assay disclosed the reversion of 
cell-migration activity with each of the agents in both cell 
lines (Fig. 2B). All three reverting agents suppressed the G0/
G1 accumulation resulting from EMT induction and reverted 
the cell cycle to the pattern of the original cells in both cell 
lines (Fig. 2C). These observations indicate that the agents are 
capable of reverting the TGF-β/FGF-2-induced EMT pheno-
type.
Alterations of Smad3, MEK/Erk, mTOR-C1/p70S6K, and 
mTOR-C2/Akt (Ser473) pathways according to EMT induction 
and reversion. The possible mechanisms underlying TGF-β/
FGF-2-induced EMT and its reversion by PP242, metformin, 
and DMSO were scrutinized by immunoblotting for phos-
phorylated Smad3, Erk1/2, p70S6K, and Akt (Ser473) (Fig. 3). 
In the PC-9 cells, the activation of the Smad3 pathway alone 
was related to EMT induction, whereas none of the 3 reverting 
agents suppressed the activated Smad3. All the agents showed 
a tendency to suppress the phosphorylation of Akt (Ser473). 
DMSO drastically and very paradoxically activated the phos-
phorylation of Erk1/2 (Fig. 3). On the contrary, in HCC-827, 
all the four pathways were related to the induction of EMT. 
As to the reverting agents, PP242 significantly suppressed 
the activated phosphorylation of Akt (Ser473) and showed a 
tendency to inhibit the activated phosphorylation of p70S6K; 
metformin significantly suppressed the activated phosphoryla-
tion of Erk1/2 and p70S6K and showed a tendency to inhibit 
the activated phosphorylation of Akt (Ser473); and DMSO 
significantly suppressed the activated phosphorylation of 
p70S6K, whereas it again significantly and paradoxically 
further activated the phosphorylation of Smad 3 and Erk1/2 
(Fig. 3).
Alterations of drug sensitivity according to EMT induction 
and reversion. Both PC-9 and HCC-827 cells exhibiting 
TGF-β/FGF-2-induced EMT were significantly resistant to 
gefitinib, compared with untreated cells, whereas treatment 
with TGF-β alone or FGF-2 alone had no effect or only a 
modest effect on sensitivity to gefitinib (Fig. 4A). On the 
contrary, PC-9 cells exhibiting TGF-β/FGF-2-induced EMT 
showed an unaltered sensitivity to cisplatin, whereas HCC-827 
cells exhibiting TGF-β/FGF-2-induced EMT were signifi-
cantly resistant to cisplatin (Fig. 4A). PP242 and metformin 
had modest re-sensitizing effects for gefitinib in cells exhib-
iting EMT induction in both cell lines, with the effects of 
DMSO being unequivocal. Although none of the agents had 
any effect on cisplatin sensitivity in the PC-9 cells, PP242 and 
DMSO had a modest re-sensitizing effect on cisplatin in the 
HCC-827 cells, whereas metformin seemingly had no effect 
on the sensitivity of the cells to cisplatin (Fig. 4A). These 
phenomena were precisely supported by the apoptosis assay. 
Apoptosis induced by gefitinib in the PC-9 and HCC-827 cells 
and apoptosis induced by cisplatin in the HCC-827 cells, but 
not in the PC-9 cells, was significantly suppressed in cells 
exhibiting the EMT phenotype, compared with the control 
cells (Fig. 4B). Nevertheless, PP242, metformin, and DMSO 
restored apoptosis with gefitinib, but not with cisplatin, in the 
PC-9 cells, whereas all three of the reverting agents restored 
apoptosis caused by either gefitinib or cisplatin that was 
suppressed in the HCC-827 cells exhibiting EMT induction 
(Fig. 4B).
Alteration of PD-L1 expression according to EMT induction 
and reversion. In the HCC-827 cells, TGF-β/FGF-2-induced 
EMT cells were related to a strong increase in PD-L1 expres-
sion, and metformin and DMSO, but not PP242, suppressed 
this phenomenon. The PC-9 cells also displayed a similar 
phenomenon, although the difference was not statistically 
significant (Fig. 5A). Fluorescent immunohistochemistry 
for PD-L1 expression on the cellular membranes supported 
these findings, except that PP242 significantly suppressed 
EMT-induced PD-L1 overexpression (Fig. 5B), in contrast 
to the absence of any effect when assessed using RT-PCR 
(Fig. 5A).
Discussion
This study, which was performed using two NSCLC cell lines 
harboring an EGFR mutation, confirmed the induction of the 
EMT using a combination of TGF-β and FGF-2. It also demon-
strated the reversion of EMT induction using any of the agents, 
PP242, metformin, or DMSO. These phenotypic changes were 
supported by morphological changes; the altered expression of 
an epithelial marker, mesenchymal markers, and slug; altered 
cell mobility; and an altered cell cycle, with the slight excep-
tion that the expression of E-cadherin was unaltered among 
the original phenotype, induced EMT phenotype, and reverted 
phenotype in PC-9 cells. This exception, however, is concor-
dant with a previously reported finding that the morphology 
and expression of E-cadherin were not significantly altered in 
PC-9 cells exhibiting EMT (25). To elucidate the mechanisms 
underlying this phenomenon, the known important pathways 
for EMT, Smad3 (2,7,9,10), MEK/Erk (2,7,8,11), mTOR-C1/
p70S6K (2,7,11) and mTOR-C2/Akt (Ser473), (2,7,26), were 
examined. The results showed that all the pathways in the 
HCC-827 cells and the Smad3 pathway in the PC-9 cells were 
correlated with EMT induction. whereas, the mechanisms 
involved in reverting the EMT seemed slightly more complex. 
PP242 significantly inhibited mTOR-C2/Akt in both cell lines 
and tended to inhibit mTOR-C1/p70S6K in HCC-827 cells; 
metformin significantly inhibited MEK/Erk and mTOR-C1/
p70S6K in HCC-827 cells and tended to inhibit mTOR-C2/
Akt in both cell lines; and DMSO inhibited mTOR-C1/
p70S6K in both cell lines but had some paradoxical effects 
on the MEK/Erk pathway. This paradoxical effect of DMSO 
KURIMOTO et al:  REvERSION OF EPITHELIAL-MESENCHYMAL TRANSITION1832
Figure 4. Alterations of sensitivity to gefitinib and cisplatin according to EMT induction and reversion. (A) MTT assay after 72 h of treatment with gefitinib 
or cisplatin showed that sensitivity to gefitinib was not significantly altered when the cells were treated with TGF-β or FGF-2 alone, whereas the combina-
tion of these 2 agents induced significant resistance to gefitinib. PP242 and metformin partly restored the sensitivity to gefitinib in both cell lines. As to the 
sensitivity to cisplatin, similar effects were only observed in the HCC-827 cells. The dots and bars represent the means and SEs (n=6, in triplicate), respectively. 
(B) Apoptotic cells were counted using Annexin V staining at 24 h after exposure to gefitinib or cisplatin, then assessed using FACS. The percentages for 
all the early apoptotic cells and for the necrotic/late apoptotic cells were then calculated. Apoptosis increased with gefitinib or cisplatin treatment in a dose-
dependent manner in the control (no TGF-β/FGF-2). In both cell lines with TGF-β/FGF-2-induced EMT, however, apoptosis was significantly suppressed after 
treatment with gefitinib. Treatment with PP242, metformin, and DMSO significantly restored the sensitivity to gefitinib, as assessed by evaluating apoptosis. 
Similar effects were also observed for the sensitivity to cisplatin in HCC-827 cells, but not in PC-9 cells. The columns and bars represent the means and SEs 
(n=3, in triplicate), respectively. Statistically significant differences (P<0.05) compared with the control (no TGF-β/FGF-2) and TGF-β/FGF-2-treated cells are 
indicated by * and ¶, respectively, in (A) and (B).
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suggests the possible involvement of other pathways in EMT, 
although no evidence to support this hypothesis is presently 
available. In addition, as also supported by the apoptosis anal-
yses, the induction and reversion of EMT were correlated with 
drug resistance to an EGFR-TKI and the ability to overcome 
resistance to an EGFR-TKI, respectively, in both cell lines, 
and an altered sensitivity to cisplatin was observed solely in 
HCC-827 cells, again with some differences in the effects of 
the three reverting agents. Interestingly, the combination of 
TGF-β and FGF-2 had significant effects on drug resistance 
in this study, whereas TGF-β or FGF-2 alone showed absent 
or equivocal effects, suggesting a synergistic effect of these 
cytokines.
The changes in drug sensitivity according to the acquisi-
tion and reversion of the EMT phenotype were consistent with 
those of previous reports, that is, a decreased sensitivity to 
gefitinib was observed in EGFR mutant NSCLC cells exhib-
iting an EMT phenotype induced by TGF (27), HGF (28), and 
IL-6 (29). A decreased sensitivity to cisplatin in NSCLC cells 
(30) and to trastuzumab in breast cancer cells (31) as a result 
of EMT induction with TGF, and to etoposide in small cell 
lung cancer cells with an HGF-induced EMT phenotype (32) 
were also reported. Previous studies have disclosed that an Erk 
inhibitor (27) and mTOR inhibitors (26,33-35) restored drug 
sensitivity affected by the EMT. In addition, metformin was 
shown to cause EMT reversion through the inhibition of the 
mTOR, Erk, and JAK/STAT3 pathways (29,31). These findings 
suggest the involvement of the Erk, mTOR, and JAK/STAT3 
pathways in EMT reversion and its relation to drug resistance. 
Although the mechanisms involved have not yet been defined, 
other agents such as crizotinib (32), resveratrol (36), tranilast 
(37), the eukaryotic initiation factor inhibitor GC7 (N1-guanyl-
1,7-diaminoheptane) (38), propolis (39), eribulin (40) and 
TTF-1 (41) have been reported to decrease EMT-induced drug 
resistance. Therefore, this study, in addition to confirming 
the restoration of drug sensitivity and EMT reversion by an 
mTOR inhibitor and metformin, provided the new findings 
that DMSO reverted the EMT and restored drug sensitivity 
through the inhibition of the mTOR-C1/p70S6K pathway and 
had some paradoxical effects on other pathways. Although 
DMSO is known to have multiple effects on cellular func-
tions, such as an increased intracellular calcium concentration 
Figure 5. Alterations in PD-L1 expression according to EMT induction and reversion. (A) Relative mRNA expression of PD-L1 normalized to that in control. 
In the HCC-827 cells, PD-L1 was upregulated in cells treated with TGF-β/FGF-2, and metformin and DMSO, but not PP242, suppressed the upregulation. 
The PC-9 cells showed a tendency toward the same results as those observed for HCC-827 cells. The columns and bars represent the means and SEs (n=3, 
in triplicate) of the relative ratio compared with the control, respectively. Statistically significant differences (P<0.05) compared with the control (no TGF-β/
FGF-2) and the TGF-β/FGF-2-treated cells are indicated by * and ¶, respectively. (B) Fluorescent immunohistochemistry demonstrating PD-L1 expression on 
the cell surface supported the findings shown in (A), except that PP242 significantly suppressed EMT-induced PD-L1 overexpression, in contrast to the absence 
of any effect when assessed using RT-PCR.
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and the differentiation of embryonal cells and leukemia cells 
(42-44), its role on modifying the EMT phenotype has not been 
reported. Furthermore, since DMSO has also been reported to 
reduce vimentin expression and to promote a fibroblast-like 
morphology in cultured rat neonatal hepatocytes (45,46), these 
observations may be reflected by the reversion of the EMT. 
DMSO also reportedly induces the differentiation of a human 
promyelocytic leukemia cell line through the activation of 
the MEK/Erk pathway (47). The activation of the MEK/Erk 
pathway was also demonstrated in this study, although the 
activation of the pathway seems to be in the opposite direction 
for EMT reversion. As the effects of DMSO on EMT reversion 
appeared to be paradoxical in this study, the biological func-
tions of DMSO should be further clarified.
This study also demonstrated a close relationship between 
PD-L1 expression and EMT induction/reversion. PD-L1 
expression on the surface of cancer cells is known to be 
important for escaping from host immunity. Although the 
mechanisms involved in regulating PD-L1 expression are not 
fully understood, a recent report also disclosed a link between 
the induction of EMT and the overexpression of PD-L1. 
This study illustrated a potential mechanism where an EMT 
activator, zinc-finger E-box-binding homeobox 1, relieved 
the microRNA-200-induced suppression of PD-L1, leading 
to CD8+ tumor-infiltrating lymphocyte-induced immuno-
suppression (48). Another recent study also demonstrated 
the overexpression of PD-L1 in the TGF-β-driven EMT 
and the downregulation of PD-L1 expression through the 
inhibition of PI3K or Erk in breast cancer cells (49). TGF-β 
is a well-known immune suppresser related to the Smad3 
and non-Smad3 pathways (6). In this study, although EMT 
induction was related to an elevation in Smad3 expression, 
its reversion was not related to a decrease in Smad3 expres-
sion, whereas PD-L1 expression was elevated in the process 
of EMT induction and was suppressed during the process 
of reversion, suggesting the involvements of the non-Smad3 
pathways in EMT-driven immune suppression, at least in the 
PC-9 and HCC-827 cells. The PI3K/Akt and MEK/Erk path-
ways, which are both common downstream signal pathways of 
ALK and EGFR, reportedly mediate the modulation of PD-L1 
expression in cancer cells with either an ALK-translocation or 
EGFR mutation (50). Taken together, these results suggest that 
EMT-related immune suppression and its reversion in cancer 
cells with activated EGFR signaling may occur as a result of 
changes in PD-L1 expression.
Many fragments of evidence regarding the EMT in cancer 
cells as it relates to immune-protection, drug sensitivity, and 
reversion have been provided by many studies. However, this 
study provided a comprehensive demonstration of the entire 
story of EMT induction and reversion, including the accom-
panying changes in drug sensitivity and immune suppression. 
Moreover, this study identified the mechanisms underlying 
these observations and suggested that different mechanisms 
may be involved in different cell lines. we believe that these 
points are the strengths of this study. The addition of DMSO to 
the list of EMT-reverting agents together with the disclosure 
of its unique roles in EMT reversion gives further strength to 
this study. Nevertheless, this study did have some limitations: 
i) the study was exclusively performed in two NSCLC cell 
lines with the same EGFR mutation, ii) the possibility that 
the observed findings might be limited to cells with activated 
EGFR cannot be excluded because the change in sensitivity to 
cisplatin was only modest, iii) the findings are limited to the 
induction of the EMT through TGF-β and FGF-2, and other 
growth factors and cytokines known to induce the EMT, such 
as HGF, insulin-like growth factor, and IL-6, were not studied, 
and iv) all the findings were derived from in vitro experiments 
lacking interactions between the tumor and cancer microen-
vironments, which are thought to be very important for some 
epigenetic changes, including EMT. The last issue seems to be 
especially crucial in the context of the relationship between the 
EMT and immune suppression, where interactions between the 
cancer cells and the host immune cells are critical. Obviously, 
further elucidation and verification of the observations in other 
cell lines, both in vitro and in vivo, are needed.
In conclusion, EMT reversion has the potential to over-
come drug resistance of cancer cells, especially for treatments 
involving molecular targeted therapy and immune checkpoint 
therapy. Further elucidation of the mechanisms underlying 
EMT reversion and the identification of more potent agents 
capable of reverting EMT are warranted for clinical applica-
tions.
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